Tag Archives: BMRN

Leerink Partners Keeps a Buy Rating on BioMarin Pharmaceutical (BMRN)

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) on September 3. The company’s shares closed last Monday at $77.98. According to TipRanks.com, Schwartz is a 4-star analyst with an average return of

BioMarin Pharmaceutical (BMRN) Has a New Rating from Leerink Partners

In a report issued on July 8, Joseph Schwartz from Leerink Partners initiated coverage with a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The company’s shares closed last Friday at $83.62. According to TipRanks.com, Schwartz is a 4-star

BioMarin Pharmaceutical (BMRN) Receives a Buy from Leerink Partners

In a report issued on June 25, Joseph Schwartz from Leerink Partners maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The company’s shares closed last Thursday at $83.91. According to TipRanks.com, Schwartz is a 4-star analyst with

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Amarin (NASDAQ: AMRN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Amarin (AMRN – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) Canaccord Genuity analyst Michelle

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Voyager Therapeutics (NASDAQ: VYGR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Voyager Therapeutics (VYGR – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) In a report

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) Wedbush analyst Liana